Posted: 05/24/2025 03:29 am
Armata Pharmaceuticals, Inc., a clinical-stage biotechnology firm known for its focus on high-purity, pathogen-specific bacteriophage therapeutics, has recently been in the limelight for its groundbreaking Phase 1b/2a diSArm study results. However, beyond its scientific strides, understanding the compensation dynamics within Armata provides valuable insight into the workings of the company.
In 2024, a notable compensation highlight was that of Dr. Mina Pastagia, the former Chief Medical Officer. Dr. Pastagia received a total compensation of $1,041,915, which included a salary of $450,917 and a bonus of $75,000, accompanied by stock awards valued at $33,800. A significant chunk of her earnings came from "all other compensation," which stood at $482,198¹. This generous compensation package mirrors Armata’s commitment to rewarding strategic leadership roles pivotal to its ongoing R&D efforts.
Looking back at 2022, Erin Butler, the former Vice President, Finance Administration, garnered a total compensation of $529,522. Despite a relatively modest salary of $275,000, Butler’s compensation prominently featured option awards amounting to $188,522². This highlights the company’s strategic use of stock options as an incentive, aligning employees’ interests with shareholder value.
Further reflecting on historical data, Steve Martin, the Chief Financial Officer in 2021, amassed a total compensation of $739,018. Martin's package demonstrated Armata’s utilization of incentive-based pay, receiving $148,320 for performance-related achievements³. This performance-oriented approach helps motivate key company executives in achieving business goals. In 2020, CEO Todd Patrick’s compensation structure was prominently driven by incentive plan compensation, which accounted for $257,750 of his $826,754 total pay⁴.
The recent positive news from the diSArm study, which showed favorable clinical outcomes and safety profiles, suggests potential growth avenues for the company⁵. However, Armata's financial performance remains under scrutiny, as indicated by its recent quarterly loss report that fell short of revenue expectations, underscoring the mixed reactions it faces in the investor community⁶. Despite the setbacks reflected in these losses, the company has successfully secured additional non-dilutive funding from the U.S. Department of Defense to support ongoing trials, signaling continued faith in its therapeutic innovations⁷.
As Armata attempts to navigate these complex landscapes, the company's stock, currently priced at $1.89, continues to display volatility, characterized by market uncertainties and speculative investor behavior⁸. The company's trajectory will largely hinge on its clinical achievements and financial management, continuing to make compensation packages a key lever in attracting and retaining talent crucial for future success.
1. Mina Pastagia Compensation Data: SEC Filings, [Link](https://www.sec.gov/Archives/edgar/data/921114/000110465925040273/0001104659-25-040273-index.htm)
2. Erin Butler 2022 Compensation Data: SEC Filings, [Link](https://www.sec.gov/Archives/edgar/data/921114/000110465924054149/0001104659-24-054149-index.htm)
3. Steve Martin Compensation Data: SEC Filings, [Link](https://www.sec.gov/Archives/edgar/data/921114/000110465922109383/0001104659-22-109383-index.htm)
4. Todd Patrick Compensation Data: SEC Filings, [Link](https://www.sec.gov/Archives/edgar/data/921114/000110465921053165/0001104659-21-053165-index.htm)
5. Armata Pharmaceuticals diSArm Study Results: PRNewswire, [Link](https://www.prnewswire.com/news-releases/armata-pharmaceuticals-announces-positive-topline-data-from-the-phase-1b2a-disarm-study-of-intravenously-administered-ap-sa02-in-complicated-staphylococcus-aureus-bacteremia-302458664.html)
6. Q1 Financial Results and Loss Reports: Zacks.com, [Link](https://www.zacks.com/stock/news/2471393/armata-pharmaceuticals-inc-armp-reports-q1-loss-lags-revenue-estimates)
7. Department of Defense Funding Announcement: PRNewswire, [Link](https://www.prnewswire.com/news-releases/armata-pharmaceuticals-receives-4-65-million-of-additional-non-dilutive-award-funding-from-the-us-department-of-defense-to-support-ongoing-disarm-clinical-trial-of-ap-sa02--302443865.html)
8. Armata Pharmaceuticals Stock Data: Current Market Snapshot.
